Suppr超能文献

罗马尼亚和德国的卵巢癌健康政策:一项比较研究。

Ovarian cancer health politics in Romania and Germany: A comparative study.

作者信息

Cobec Ionut Marcel, Sas Ioan, Moatar Aurica Elisabeta, Moleriu Lavinia, Rempen Andreas

机构信息

Clinic of Obstetrics and Gynecology, Diakonie-Klinikum Schwäbisch Hall, D-74523 Schwäbisch Hall, Germany.

Department of Obstetrics and Gynecology, 'Victor Babeș' University of Medicine and Pharmacy of Timisoara, 300041 Timisoara, Romania.

出版信息

Exp Ther Med. 2021 Nov;22(5):1217. doi: 10.3892/etm.2021.10651. Epub 2021 Aug 26.

Abstract

Ovarian cancer is known to have a poor prognosis, being the 7th most common cancer type in women with regard to incidence and mortality worldwide. The present study underlines the importance of early diagnosis and prevention management of ovarian cancer. This study is a hospital-based case-control study that was conducted at the same time in two similar hospitals from different countries, Romania and Germany, over three years. The results showed that significant differences were identified for the two groups with regards to the age factor (P<0.001). A risk analysis was performed to determine whether the patients from Romania were exposed to a risk factor. The risk of developing deadly diseases was deemed much higher owing to insufficient protocols or informative programs in Romania. The medical information, early diagnosis and standardized therapy with optimum treatment based on health policy and health care systems, play a key role concerning the management and prognosis of ovarian cancer which are different from country to country.

摘要

众所周知,卵巢癌预后较差,在全球范围内,就发病率和死亡率而言,是女性中第七大常见癌症类型。本研究强调了卵巢癌早期诊断和预防管理的重要性。本研究是一项基于医院的病例对照研究,在三年时间里,于罗马尼亚和德国这两个不同国家的两所相似医院同时开展。结果显示,两组在年龄因素方面存在显著差异(P<0.001)。进行了风险分析,以确定罗马尼亚的患者是否暴露于风险因素。由于罗马尼亚的方案或信息项目不足,患致命疾病的风险被认为要高得多。医疗信息、早期诊断以及基于卫生政策和医疗保健系统的最佳治疗的标准化疗法,在卵巢癌的管理和预后方面起着关键作用,而这在不同国家是不同的。

本文引用的文献

1
Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990-2017.
Gynecol Oncol. 2020 Oct;159(1):239-247. doi: 10.1016/j.ygyno.2020.07.008. Epub 2020 Jul 18.
2
The prevalence of malignant and borderline ovarian cancer in pre- and post-menopausal Chinese women.
Oncotarget. 2017 Aug 22;8(46):80589-80594. doi: 10.18632/oncotarget.20384. eCollection 2017 Oct 6.
3
Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
Gynecol Oncol. 2017 Jun;145(3):486-492. doi: 10.1016/j.ygyno.2017.03.016. Epub 2017 Mar 31.
4
Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2).
Gynecol Oncol. 2017 Feb;144(2):396-404. doi: 10.1016/j.ygyno.2016.11.019. Epub 2016 Dec 2.
5
Platelet Derived Growth Factor BB: A "Must-have" Therapeutic Target "Redivivus" in Ovarian Cancer.
Cancer Genomics Proteomics. 2016;13(6):511-517. doi: 10.21873/cgp.20014.
6
Podoplanin as Key Player of Tumor Progression and Lymph Vessel Proliferation in Ovarian Cancer.
Anticancer Res. 2016 Oct;36(10):5265-5272. doi: 10.21873/anticanres.11097.
7
Staging for low malignant potential ovarian tumors: a global perspective.
Am J Obstet Gynecol. 2016 Aug;215(2):153-168.e2. doi: 10.1016/j.ajog.2016.04.035. Epub 2016 Apr 27.
10
Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.
Pharmgenomics Pers Med. 2013 Sep 25;6:113-25. doi: 10.2147/PGPM.S24943.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验